Business
CIRCULAR & GENERAL MEETING NOTIFICATION
CIRCULAR & GENERAL MEETING NOTIFICATION.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 2175V Oxford Biomedica PLC 11 December 2013 \n \n\n\n\n\n\nFOR IMMEDIATE RELEASE\n\n\n\n\n\n\n\n \nOXFORD BIOMEDICA PLC\nCIRCULAR & GENERAL MEETING NOTIFICATION\n \nOxford UK - 11 December 2013: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Company\") (LSE: OXB) gives notice that, further to the announcement on 19 November 2013 of the proposed up to £5 million secured loan facility agreement with its largest shareholder, the Vulpes Life Sciences Fund, a circular to shareholders was posted yesterday and is available on the \"Investors\" section of the Company's website at www.oxfordbiomedica.co.uk. \n \nA copy of this document has been submitted to the National Storage Mechanism and will shortly be available for inspection at http://www.hemscott.com/nsm.do. \n \nOxford BioMedica plc also announces that a General Meeting will be held on Monday 6 January 2014 at 10.00 a.m. at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH.\n \n- Ends -\n \n\n\n\n\n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\n \nOxford BioMedica plc: \nJohn Dawson, Chief Executive Officer\nTim Watts, Chief Financial Officer\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nMedia Enquiries:\nMary-Jane Elliott/Emma Thompson/Matthew Neal\nConsilium Strategic Communications\n\n\n \nTel: +44 (0)20 7920 2354\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to editors\n \n1. About Oxford BioMedica®\nOxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.\n \n\nThis information is provide...